Castleark Management’s Xenon Pharmaceuticals XENE Stock Holding History

Castleark Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.73M	Sell	61,763 -2,800	-4%	-$155K	0.1%	180
2026 Q1	$3.75M	Buy	+64,563	New	+$2.97M	0.12%	170
2023 Q3	–	Sell	-94,490	Closed	-$3.64M	–	321
2023 Q2	$3.64M	Buy	94,490 +16,750	+22%	+$666K	0.16%	137
2023 Q1	$2.78M	Hold	77,740	–	–	0.14%	147
2022 Q4	$3.07M	Buy	+77,740	New	+$2.83M	0.16%	138

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Castleark Management's XENE Position: Q2 2026 in Review

Castleark Management reduced its Xenon Pharmaceuticals (XENE) stake by 4.3% in Q2 2026, selling an estimated $155K and leaving 61,763 shares worth $3.73M. The position accounts for 0.1% of the portfolio, ranked #180.

Castleark Management first reported a position in XENE in Q4 2022 and has held it in 5 quarters since. The position peaked at $3.75M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Castleark Management held 61,763 shares of Xenon Pharmaceuticals worth $3.73M as of Q2 2026.
Castleark Management sold 2,800 Xenon Pharmaceuticals shares in Q2 2026, an estimated $155K.
Xenon Pharmaceuticals made up 0.1% of Castleark Management's portfolio in Q2 2026, its #180 holding.
Castleark Management first reported a position in Xenon Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
Castleark Management's Xenon Pharmaceuticals position peaked at $3.75M in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.